Literature DB >> 34080545

Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study.

Cayley Russell1, Farihah Ali2, Frishta Nafeh3, Jürgen Rehm4, Sean LeBlanc5, Tara Elton-Marshall6.   

Abstract

INTRODUCTION: Closures and reductions in capacity of select health and social services in response to the COVID-19 pandemic may have placed people who use drugs (PWUD) at a disproportionately increased risk for experiencing harms, and resulted in critical treatment disruptions. We conducted the current national study among a cohort of PWUD to understand how COVID-19 has affected service access, including any significant impacts PWUD may have experienced. Results will contribute to the evidence base for informing future pandemic and public health policy planning for vulnerable populations.
METHODS: The project involved qualitative telephone-based interviews with 196 adult (aged 18+) PWUD from across Canada. Eligibility criteria included daily or weekly use of psychoactive substance(s), and/or current enrollment in opioid agonist treatment (OAT). Data collection took place between May and July 2020. Data underwent thematic analyses, and common themes informed the results.
RESULTS: Most participants experienced detrimental service access issues and treatment disruptions during COVID-19, including reduced access to harm reduction services, OAT, withdrawal management and treatment services, medical professionals (e.g., addictions and mental health counseling), shelters/housing, and food banks. Positive impacts included greater access to OAT take-home 'carries' and prescription deliveries. Decreases in service capacity resulted in increased health issues and risky substance use behaviors among PWUD, such as unaccompanied substance use, sharing/re-use of supplies, and overdose events.
CONCLUSIONS: Reductions in the accessibility of critical services PWUD rely on during COVID-19 has increased existent substance use and health issues among PWUD, while decreasing their ability to mitigate risks related to substance use. Thus, the expansion of the depth and breadth of support options is crucial. Services must remain open and flexible to the unique needs of PWUD during COVID-19, while novel and effective adaptations and interventions should remain available and accessible post-COVID-19.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Addiction; COVID-19; Harm reduction; Public health; Service access; Treatment

Year:  2021        PMID: 34080545     DOI: 10.1016/j.jsat.2021.108374

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  20 in total

1.  The Impact of COVID-19 on Self-Reported Substance Use, Well-Being, and Functioning Among United States Veterans: A Cross-Sectional Study.

Authors:  Erin D Reilly; Elizabeth S Chamberlin; Brooke A Duarte; J Irene Harris; Steven D Shirk; Megan M Kelly
Journal:  Front Psychol       Date:  2022-04-11

2.  Changes in Substance Use Among People Seeking Alcohol and Other Drug Treatment During the COVID-19 Pandemic: Evaluating Mental Health Outcomes and Resilience.

Authors:  Molly Carlyle; Janni Leung; Zoe C Walter; Jennifer Juckel; Caroline Salom; Catherine A Quinn; Lily Davidson; Rhiannon Ellem; Grace Newland; Leanne Hides
Journal:  Subst Abuse       Date:  2021-12-06

Review 3.  The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data.

Authors:  Sameer Imtiaz; Frishta Nafeh; Cayley Russell; Farihah Ali; Tara Elton-Marshall; Jürgen Rehm
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-11-29

4.  Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic-Is an update of legal restrictions warranted?

Authors:  Maximilian Meyer; Johannes Strasser; Patrick Köck; Marc Walter; Marc Vogel; Kenneth M Dürsteler
Journal:  Int J Drug Policy       Date:  2021-11-26

5.  Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey.

Authors:  Sachini Bandara; Hannah Maniates; Eric Hulsey; Jennifer S Smith; Ellen DiDomenico; Elizabeth A Stuart; Brendan Saloner; Noa Krawczyk
Journal:  BMC Health Serv Res       Date:  2022-03-30       Impact factor: 2.655

6.  Navigating intersecting public health crises: a qualitative study of people with opioid use disorders' experiences during the COVID-19 pandemic.

Authors:  Dennis P Watson; Monte D Staton; Christine E Grella; Christy K Scott; Michael L Dennis
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-03-18

7.  A multicentric survey among patients with substance use disorders during the COVID-19 lockdown in India.

Authors:  Sidharth Arya; Abhishek Ghosh; Shree Mishra; Mukesh Kumar Swami; Sambhu Prasad; Aditya Somani; Aniruddha Basu; Kshitiz Sharma; Susanta Kumar Padhy; Naresh Nebhinani; Lokesh Kumar Singh; Shinjini Choudhury; Debasish Basu; Rajiv Gupta
Journal:  Indian J Psychiatry       Date:  2022-01-21       Impact factor: 1.759

8.  The impact of COVID-19 on access to harm reduction, substance use treatment and recovery services in Scotland: a qualitative study.

Authors:  Joe Schofield; Joshua Dumbrell; Catriona Matheson; Tessa Parkes; Angus Bancroft
Journal:  BMC Public Health       Date:  2022-03-15       Impact factor: 3.295

9.  COVID 19-impact on substance use treatment utilization and provision in South Africa.

Authors:  Nadine Harker; Kim Johnson; Jodilee Erasmus; Bronwyn Myers
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-03-03

10.  Experiences of people with opioid use disorder during the COVID-19 pandemic: A qualitative study.

Authors:  Lexis R Galarneau; Jesse Hilburt; Zoe R O'Neill; Jane A Buxton; Frank X Scheuermeyer; Kathryn Dong; Janusz Kaczorowski; Aaron M Orkin; Skye Pamela Barbic; Misty Bath; Jessica Moe; Isabelle Miles; Dianne Tobin; Sherry Grier; Emma Garrod; Andrew Kestler
Journal:  PLoS One       Date:  2021-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.